NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
May 27 (Reuters) - Neuropace Inc NPCE.O:
NEUROPACE INC: REAFFIRMS ITS PREVIOUSLY ISSUED FULL-YEAR 2025 FINANCIAL GUIDANCE
NEUROPACE INC - COMPLETES PRIMARY ENDPOINT ANALYSIS FOR IDIOPATHIC GENERALIZED EPILEPSY STUDY
NEUROPACE INC - STUDY MEETS 12-WEEK POST-IMPLANT SAFETY ENDPOINT
NEUROPACE INC - PRELIMINARY DATA SHOWS FAVORABLE SEIZURE REDUCTION RATES FOR RNS SYSTEM
NEUROPACE - PRIMARY EFFECTIVENESS ENDPOINT NOT STATISTICALLY SIGNIFICANT IN OVERALL POPULATION
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

IonQ vs. Rigetti Computing: Which Quantum Computing Stock Has the Edge Now?

Is Bitcoin Reaching a Local Top? Institutional Demand vs. Retail Sentiment at $70,000

Memory Chips Drive Samsung Earnings Surge, But Stock Price Opens High and Closes Lower: Why?

Tradingkey








